Zoloft adds PMDD indication
This article was originally published in Pharmaceutical Approvals Monthly
Executive SummaryPfizer's Zoloft (sertraline) is approved for premenstrual dysphoric disorder May 16. Zoloft is the second selective serotonin reuptake inhibitor to gain the indicatio
You may also be interested in...
Biocon and Mylan press ahead with plans to broaden patient access in the US to biosimilar pegfilgrastim and are enthused with the initial uptake for their trastuzumab biosimilar ahead of more upcoming competition. A mid-2020 US launch for partnered insulin glargine is also on course.
Drug companies in the EU explain how a new pilot scheme on national-level scientific advice service can benefit drug developers.
India’s Indoco Remedies is looking for healthy revenue growth in the coming fiscal year after beating market estimates with a 70.4% year-on-year jump in after-tax profit in its financial third quarter, propelled by strong revenues from domestic and international markets.